Asston Pharma to raise ₹27.7 cr via preferential issue, 28% dilution
The nano-cap pharma company is selling a 28% stake to non-promoter investors, including a 12% block to Vijay Rathee, in a deal that could reshape control and pricing.
What's new
- Board approved preferential issue of 24.1L shares at ₹115 each, raising ₹27.72 cr.
- Largest allottee Vijay Rathee to hold 12.06% post-issue; Vijaylaxmi Infra gets 7.16%.
- Issue represents ~28% dilution; EGM set for 31 July for shareholder nod.
Why this matters
At a market cap of just ₹69 cr, this ₹27.72 cr infusion is over 40% of the company's value. Existing shareholders face severe 28% dilution, and the entry of a 12% holder changes governance. The cash could fund growth, but the price is control.
What we're watching
- Whether shareholders approve the issue at the 31 July EGM.
- How the stock trades post-announcement given dilution and new investor entry.
- Any specific utilisation plans for the ₹27.72 cr.
The full read
Asston Pharmaceuticals, a nano-cap with a market cap of ₹69 cr, is raising ₹27.72 crore by selling 24.1 lakh shares at ₹115 each to non-promoter investors. The sum is over 40% of the company's current market value. The dilution is steep: 28% of existing equity heads to new holders. Vijay Rathee alone will own 12.06% post-issue, and Vijaylaxmi Infra Projects gets 7.16%. The EGM is on 31 July; regulatory approvals are still pending. For a company with trailing ROE of 40.4% and low debt, the cash could be used to scale or for acquisitions. But at this price, existing shareholders are ceding a large chunk of control. The open question is whether the stock reprices lower to reflect the dilution or higher to reflect the capital.
Questions answered
- Why is Asston Pharma raising funds through a preferential issue?
- The board approved the issue to raise ₹27.72 cr from non-promoter investors. The exact use of funds is not specified in the filing.
- How much dilution do existing shareholders face?
- The issue of 24.1 lakh shares represents roughly 28% dilution to existing equity, based on the pre-issue share count.
- Who are the new investors, and what stakes will they hold?
- Vijay Rathee will hold 12.06% post-issue, and Vijaylaxmi Infra Projects will hold 7.16%. Other allottees are not individually named in the filing.
- What is the pricing of the issue relative to the current stock price?
- The issue price is ₹115 per share. The current market price is not disclosed in the filing, so a comparison cannot be made.
- When will the issue be completed, and what are the next steps?
- An EGM is scheduled for 31 July to obtain shareholder consent. The issuance is also subject to regulatory approvals. A completion timeline is not provided.
- How will the funds be used?
- The filing does not specify the utilisation plans for the ₹27.72 crore raised. Investors will need to await further disclosure from the company.